Edition:
United Kingdom

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

140.31USD
18 Apr 2019
Change (% chg)

$0.28 (+0.20%)
Prev Close
$140.03
Open
$140.16
Day's High
$141.26
Day's Low
$136.77
Volume
434,481
Avg. Vol
687,707
52-wk High
$197.00
52-wk Low
$125.84

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.32
Market Cap(Mil.): $46,685.38
Shares Outstanding(Mil.): 332.73
Dividend: 0.74
Yield (%): 2.11

Financials

  AGN.N Industry Sector
P/E (TTM): -- 58.59 59.19
EPS (TTM): -15.37 -- --
ROI: -4.99 12.14 11.77
ROE: -7.70 13.10 12.61

Proxy firms back Allergan in fight against Appaloosa

Two leading shareholder advisory firms threw their support behind Allergan Plc's management by recommending that investors vote against billionaire investor David Tepper's proposal that the Botox maker immediately split the roles of chief executive officer and chairman.

15 Apr 2019

UPDATE 3-Proxy firms back Allergan in fight against Appaloosa

April 15 Two leading shareholder advisory firms threw their support behind Allergan Plc's management by recommending that investors vote against billionaire investor David Tepper's proposal that the Botox maker immediately split the roles of chief executive officer and chairman.

15 Apr 2019

U.S. Supreme Court rejects Allergan bid to use tribe to shield drug patents

WASHINGTON The U.S. Supreme Court on Monday cast aside pharmaceutical company Allergan Plc's unorthodox bid to shield patents from a federal administrative court's review by transferring them to a Native American tribe.

15 Apr 2019

UPDATE 1-U.S. Supreme Court rejects Allergan bid to use tribe to shield drug patents

WASHINGTON, April 15 The U.S. Supreme Court on Monday cast aside pharmaceutical company Allergan Plc's unorthodox bid to shield patents from a federal administrative court's review by transferring them to a Native American tribe.

15 Apr 2019

U.S. Supreme Court rejects Allergan bid to shield drug patents from review

WASHINGTON, April 15 The U.S. Supreme Court on Monday cast aside pharmaceutical company Allergan Plc's unorthodox bid to shield patents from a federal administrative court's review by transferring them to a Native American tribe.

15 Apr 2019

REFILE-Proxy firms Glass Lewis and ISS back Allergan in fight against Appaloosa

April 15 Allergan Plc said on Monday that proxy advisory firms Institutional Shareholder Services Inc and Glass Lewis & Co had urged its shareholders to vote against hedge fund Appaloosa LP's proposal to immediately separate the drugmaker's chief executive officer and chairman roles.

15 Apr 2019

Health Canada plans to suspend Allergan's breast implant license

Health Canada plans to suspend the license for Allergan Plc's Biocell breast implant due to the risk of a rare cancer linked to such implants, the regulator said in a notice to the Botox-maker on Thursday.

04 Apr 2019

UPDATE 2-Health Canada plans to suspend Allergan's breast implant license

April 4 Health Canada plans to suspend the license for Allergan Plc's Biocell breast implant due to the risk of a rare cancer linked to such implants, the regulator said in a notice to the Botox-maker on Thursday.

04 Apr 2019

Health Canada plans to suspend Allergan's breast implant license

April 4 The Canadian health regulator said on Thursday it was advising Allergan Plc that it plans to suspend the license for the Botox-maker's Biocell breast implants.

04 Apr 2019

BRIEF-Allergan And Molecular Partners Announce Topline Safety Results From Maple Study Of Abicipar Pegol

* ALLERGAN AND MOLECULAR PARTNERS ANNOUNCE TOPLINE SAFETY RESULTS FROM MAPLE STUDY OF ABICIPAR PEGOL

02 Apr 2019

Earnings vs. Estimates